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SUMMARY 
The binding of agonists and antagonists to a2-adrenergic recep-
tors of human platelets was studied. The receptors showed 
homogeneaus affinities for antagonists but two affinity states for 
the agonist (-)-epinephrine, which were modulated by guanine 
nucleotides. Van't Hoffplots of antagonist binding had a break 
point at about 18° and considerable diversity between 18° and 
0°. Agonist binding to both affinity states showed a similar break 
point; agonist binding to the high affinity state was characterized 
by a large entropy component compared to the low affinity state. 
This entropy component was reduced at higher concentrations 
of sodium, indicating that it may be due to Iiberation of sodium 
ions. Measurements of the fluorescence of 1-anilin-8-naphtha-
lenesulfonate showed thermotropic phase transitions of the 
The binding of various ligands to their receptors has been 
shown to be a temperature-rlependent process. Although this 
dependence has been observed in many of the earlier studies, 
the thermodynamic parameters of this process have only re-
cently been used to characterize the interaction of different 
ligands with a given receptor. With this approach Weiland et 
al. ( 1) investigated agonist and antagonist binding to the ß-
adrenergic receptor in order to study the question of why 
agonist occupation of a receptor Ieads to a response and antag-
onist occupation does not. They described fundamental differ-
ences between agonist and antagonist binding, the agonist 
binding being enthalpy driven and the antagonist binding, 
entropy driven. Similar differences have been observed in other 
receptor systems (2, 3). 
However, these analyses do not take into account the exist-
ence of different states of agonist affinity which have been 
described for most receptors coupled to adenylate cyclase. 
These differences seem to be induced by coupling of the recep-
tor to the guanine nucleotide-binding proteins (stimulatory or 
inhibitory), which Ieads to a considerable increase of the affin-
ity for agonists (4). The two affinity states can be discriminated 
by use of curve fitting to competition or saturation curves (5). 
An analysis of the temperature dependence of agonist binding 
to the two affinity states of the A1 (ß;) adenosine receptor 
platelet membranes at about 17°. The transition temperature 
was decreased to about 12° by addition of 1 0 mM octanoic acid. 
Octanoic acidalso shifted the break points of the van't Hoffplot 
of antagonist and low affinity agonist binding from 18° to 12°. 
High affinity agonist binding, however, remained unchanged. lt 
is concluded that agonist-specific thennodynamic characteristics 
of Iigand binding to a2-receptors of human platelets can only be 
investigated by regarding differences between high and low 
affinity agonist binding. These differences include an entropy 
increase upon Iigand binding, which is in part due to enhanced 
Iiberation of sodium ions, and a loss of sensitivity to fluidity 
changes in the outer layer of the plasma membrane. 
showed very marked thermodynamic differences between the 
binding to the two affinity states (6). Agonist binding to the 
low affinity state was enthalpy driven in a manner similar to 
that of antagonist binding, whereas agonist binding to the high 
affinity state was entropy driven and thus clearly different from 
the former. A possible explanationisthat the thermodynamic 
differences are due to the interaction of the receptor with Ni 
and that they do not depend only on the ligand-receptor inter-
action. 
The present study was undertaken to see whether these 
findings are true also for other receptors coupled to adenylate 
cyclase. The model chosen was the a2-adrenergic receptor of 
human platelets. Human platelets appear to have adrenergic 
receptors of the a2-subtype which mediate an inhibition of 
adenylate cyclase and induce aggregation. The receptors have 
been identified in binding sturlies with various radioligands of 
which [3H]yohimbine appears to be the most useful (7). As has 
been reported for a variety of adenylate cyclase-coupled recep-
tors, the a2-receptor of human platelets seems to exist in two 
affinity states for agonists, the high affinity state probably 
representing a complex ofreceptor and Ni protein (8). The high 
affinity state is promoted by Mg2+ and other divalent cations 
and the low affinity state by guanine nucleotides (8). The aim 
of the present study was to describe the temperature depend-
ABBREVIATIONS: N1, the inhibitory guanine nucleotide-binding protein; GppNHp, 5 '~uanylylimidodiphosphate; ANS, 1-anilinc:HJ-naphthalenesulfon-
ate; EDTA, ethylenediaminetetraacetic acid. 
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ence of the binding of antagonists and of agonists to the two 
affinity states, in order to elucidate the mechanisms involved 
in receptor activation, and the role of the physical state of the 
plasma membrane in this process. 
Experimental Procedures 
Materials 
e'H]Yohimbine (specific activity 85.5 Ci/mmol) was obtained from 
New England NuclearGmbH (Dreieich, Federal Republic ofGermany). 
Phentolamine methane sulfonate and tolazoline hydrochloride were 
kindly provided by CIBA-Geigy (Wehr, Federal Republic of Germany). 
Rauwalseine hydrochloride was from Roth AG (Karlsruhe, Federal 
Republic of Germany); yohimbine hydrochloride and epinephrine hy-
drochloride were from Sigma GmbH (München, Federal Republic of 
Germany). GppNHp was purchased from Boehringer Mannheim 
(Mannheim, Federal Republic of Germany) and ANS was purchased 
from Serva (Heidelberg, Federal Republic of Germany). All other 
chemieals were from standard commercial sources. 
Methods 
Preparation of human platelet membranes. Fresh platelet-rich 
plasma was obtained from a local blood bank. Residual erythrocytes 
and leukocytes were removed by two centrifugation steps at 400 x g 
for 10 min. Membranes were prepared in a manner analogous tothat 
described by Hoffman et al. (8). The platelets were washed three times 
in 150 mM NaCI, 50 mM Tris-HCI, 20 mM EDTA, pH 7.4, with 
centrifugations at 16,000 X g for 15 min at room temperature. The final 
pellets were homogenized in 5 mM Tris-HCI, 5 mM EDTA, pH 7.5, at 
4 • with 30 strokes of a glass-Teflon homogenizer, frozen in liquid 
nitrogen, and stored at -so·. 
Before their use in the binding assay, the membranes were thawed, 
homogenized as above, and washed three times with the same hypotonic 
buffer with centrifugations at 39,000 x g for 15 min at 4". The pellet 
was finally resuspended in 50 mM Tris-HCI, 10 mM MgC12 at pH 7.5. 
Protein was measured according to the method of Lowry et al. (9). 
Binding aaay. Binding of (3H]yohimbine (in general, 2 nM) was 
done in a total volume of 250 pl. Tris-HCI (50 mM), 10 mM MgC12, pH 
7.5, was used as a buffer system. The incubation was started by addition 
of approximately 100 pg of membrane protein and Iasted from 20 min 
at 37" to 240 min at o·. Steady state was assured under all conditions 
by using these incubation times. The reactions were terminated by 
rapid filtration through Whatman GF /B glass-fiber filters followed by 
two washes with 4 ml of ice-cold incubation buffer. Nonspecific binding 
was measured in the presence of 10 pM phentolamine. 
ANS nuorescence measurement. The fluorescence of ANS in the 
presence of platelet membranes (400 pg/ml) was measured essentially 
as described by Träuble (10). It was recorded at varying temperatures 
spectrofluorometrically with an excitation and emission wave length 
(width) of 380 nm (±5) and 480 nm (±10). 
Data Analysis 
Steady state binding data were analyzed by a nonlinear regression 
modeling method providing estimates of Ko or K; and B~ values (5). 
lf states of high and low affinity are observed, KH and KL denote the 
respective K0 or K; values, and RH and RL represent the percentage of 
receptors in the high or low affinity state. lmprovement of the fit 
assuming two states was considered significant if p values of less than 
0.001 were obtained in an F test. Kinetic data were fitted by nonlinear 
regression to the equations described (6). 
Thermodynamic parameters were calculated from van't Hoffplots 
as described by Weiland et al. (1) using the following equations: (a) 
aa· = -R·T·lnKA, (b) AH" = -a·R, and (c) as· = (Mr- aG")/T, 
where AG" (kcal/mol) is the Gibbs free energy change, MI" (kcal/mol), 
the enthalpy change, and tlS" (cal/mol-deg), the entropy change; a is 
Ligand Binding to a1·Receptora 229 
the slope of the van't Hoffplot and R is the gas constant (1.99 cal/ 
mol-deg). Linearregressions with one or more components were fitted 
to van't Hoffplots and fluorescence measurement plots as described 
by Livingstone and Schachter (11). This allows the determination of 
best fits and break points. 
Results 
The binding of [3H)yohimbine to human platelet membranes 
was saturable with a single component at all temperatures 
(Table 1). No changes of the number of receptor sites were 
found at different temperatures, but the affinity of the receptors 
for [3H)yohimbine varied as a function ofthe temperature. The 
K0 values were clearly higher at the extremes of the tempera-
ture scale. GppNHp (100 pM) bad no effect on either B_. or 
Ko values at any ofthe temperatures studied (data not shown), 
which is in agreement with reports from other groups (7, 8). 
When Mg2+ was omitted from the incubation buffer, the marked 
influence oftemperature on the Ko values was almost abolished. 
The K0 values ranged from 1.5 nM at oo to 1.1 nM at 18". In 
addition, at higher temperatures, binding in the absence of 
Mg2+ began to decline relatively early (20 min at 37°) and 
rapidly (20%/hr at 37°); this probably indicates thermal inac-
tivation of the receptor. For these reasons, Mg2+ was present 
in all other experiments. 
The Ko values for [3H]yohimbine were used to evaluate 
competition of various a2-receptor antagonists for (3H]yohim-
bine binding. Fig. 1 shows the competition curves of phentol-
amine at various temperatures. lt demonstrates the higher 
affinity of this compound at lower temperatures. In each case 
the competition curves were monophasic, again confirming the 
notion that the a2-receptor does not show heterogeneity for 
antagonists. GppNHp (100 pM) had no effect on the competi-
tion curve of phentolamine or any other antagonist. Consis-
tently, a plateau was achieved at concentrations of phentol-
amine above 0.5 p.M. Thus, 10 pM phentolamine could be used 
at all temperatures to define the nonspecific binding of (3H) 
yohimbine. 
The competition data were quantitatively analyzed by con-
structingvan't Hoffplots for various antagonists (Fig. 2). These 
plots show two features: for all compounds the data were best 
fitted by a two-component model, indicating a break point at 
about 18°, whereas the lines are similar in the temperature 
range between 37• and 18° and they show considerable diver-
gence between 18• and o•. These differences can be seen in the 
thermodynamic parameters calculated for ao· and 10" (Table 
2). At higher temperatures the bindingofall antagonists was 
largely enthalpy driven, with small or even unfavorable (tola-
zoline) entropy components. At lower temperatures the binding 
TABLE 1 
Binding parametera for Nturation of [~Ji)yohimbine binding to 
platelet membranea 
Human platelet membranes were incubated with 0.2-20 rw (~]yohimbine as 
described under Experimental Prooedlns (Methods). K" values (95% confidenoe 
Iimits) and s_ values (± SE) wera calculated by nonlinear curve fitting to the 
saturation c:uves. Only one state of homogei180US affinity was detected. Oata are 
from ttne separate experiments. 
•c n11 fmol/mg pnlein 
0 5.21 (4.26-6.38) 245.2 ± 15.2 
12 2.33 (1.93-2.82) 237.4 ± 11.7 
25 2.34 (1.74-3.14) 238.9 ± 30.1 
37 3.95 (3.24-4.81) 219.9 ± 12.6 
• 0 
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Fig. 1. Competition for [3H]yohimbine binding to human platelet mem-
branes by phentalamine. lncubations using 2 nM (3H)yohimbine were 
carried out at varying temperatures, and K1 values were calculated by 
nonlinear curve fitting as described under Experimental Procedures 
(Methods). All curves were monophasic, and the K, values for phentol-
amine at the respective temperatures were: 2.3 nM (0°), 2.7 nM (12°), 
4.6 nM (25°), and 9.0 nM (37°). Values are the means of three separate 
experiments. 
21 
20 
19 
16 
15 
14 
3,....7 _ ___,25 ___ 1"T"2 __ _,o 1•c I 
,./!~. .-• Phentotamine /./ \..-'•-/•//·~. "'· 
. /~ . '\. ""' 
• •/ '• • Yohimtine 
/ ""' • • Rauwalseine ~· Totazotine 
............... 
.............. 
.I 
I 
I 
• 
3.2 3.3 3.4 3.5 36 3.7 
f-101(.KI 
Fig. 2. van't Hoffplots for antagonist binding to arreceptors of human 
platelets. Competition experiments using 2 nM (3H)yohimbine were car-
ried out at various temperatures and analyzed as described in the legend 
to Fig. 1. KA values are 1/K, for the respective antagonists at the indicated 
temperatures. Linearregressions to the data points were performedas 
described under Experimental Procedures (Methods). Values are the 
means of three separate experiments for each data point. 
of all antagonists was largely entropy driven; there remained a 
negative (favorable) change in enthalpy for tolazoline and 
phentolamine, whereas yohimbine and rauwalseine bad an un-
favorable positive enthalpy change. 
A similar analysis was also performed for the binding of the 
agonist (- )-epinephrine. Fig. 3 shows the competition for [3H] 
yohimbine binding by (-)-epinephrine at o· and 18.5 •. In the 
TABLE2 
Thermodynamic parametera of entegonist binding to human 
platelet arreceptors 
K1 values were obtained by nonUnear curve fitting of competition curves against 
['H]yohimblne at various temperatures. Changes in free energy (~G 0 ), enthalpy 
(M# 0 ), and entropy(M 0 ) ofbinding at 10• and 30• werecalculatedfrom the van't 
Hoff plots (Fig. 2) as described under Experimental Prooedures (Methods). 
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Yohimbine 
Rauwalseine 
Phentalamine 
Talazaline 
At30° 
Yohimbine 
Rauwalseine 
Phentalamine 
Talazaline 
AG• AH• AS• 
kcal/mol cal/ 
mol·deg 
-11.1 +8.0 +67.4 
-10.9 +11.5 +79.1 
-11.1 -2.6 +30.2 
-9.2 -4.8 +15.6 
-11.8 -6.4 +17.7 
-11.7 -7.3 +14.5 
-11.4 -9.8 +5.4 
-9.1 -16.8 -25.3 
Concentration of 1-1 epineptrile IMI 
Fag. 3. Competition for (3H]yohimbine binding to human platelet mem-
branes by (-)-epinephrine. lncubations using 2 nM [3H]yohimbine were 
carried out at 0° and 18.5° in the absence and presence of 100 pM 
GppNHp as described under Experimental Procedures (Methods). Non-
linear curve fitting gave best fits assuming two affinity states for (-)-
epinephrine in the absence and one in the presence of GppNHp, and the 
fallowing estimates were obtained: At 0°: without GppNHp, KH 4.1 nM, 
KL 146 nM, RH 37%, RL 63%; with GppNHp, KL 151 nM, RL 100%. At 
18.5°: without GppNHp, KH 1.7 nM, KL 146 nM, RH 61%, RL 39%; with 
GppNHp, KL 159 nM, RL 100%. Values are the means of five separate 
experiments. 
absence of GppNHp, the competition curves were biphasic at 
both temperatures, and data were best fitted to a model assum-
ing two affinity states for the agonist. In the presence of 100 
pM GppNHp, a homogeneaus population of receptors with low 
affinity for (-)-epinephrine was seen. The Ki values for the 
latter agree reasonably weil with the Ki values for the low 
affinity state in the absence of GppNHp, suggesting that 
GppNHp induces the low affinity state of the a2-receptor (8). 
An increase in temperature from o· to 18.5 ° decreased the KH 
with little change of the KL. The proportion of the receptors in 
the high affinity state was lower at low temperatures. 
These effects were also studied at various temperatures (Ta-
ble 3; see Fig. 7, open symbols). Again, the data were best fitted 
by assuming two components and a break point at about 18•, 
both for the high and the low affinity states. The thermody-
namic parameters calculated from the plot (Table 3) showed 
that the binding of (-)-epinephrine to both affinity states was 
,, 
.· 
TABLE3 
Thermodynamic parameters of ( -)-epinephrine binding to human 
platelet aa·receptors 
K1 values were obtained by nonlinear curve fitting of competition curves against 
(~]yohimbine at various temperatures. Changes in free energy (äG 0 ), enthalpy 
(11H 0 ), and entropy (.1S 0 ) of binding at 10° and 30• were calculated from the van't 
Hoffplots (open symbols in Fig. 7) as described under Experimental Procedures 
(Methods). 
.1Go .1f10 .,1SO 
kcalfmol Caf/ 
mol·deg 
At 10° 
High affinity state -11.2 +6.3 +61.8 
Low affinity state -8.8 -0.3 +30.1 
At 30° 
High affinity state -11.8 -9.7 +6.7 
Low affinity state -9.0 -11.6 -8.9 
largely entropy driven at 10° and enthalpy driven at 30°. At 
10° there was an unfavorable positive enthalpy change for the 
high affinity state, but there remained a favorable negative 
enthalpy change for the low affinity state. At 30° a positive 
entropy component contributed to the binding reaction to the 
high affinity state, which was not seen for the low affinity 
state. 
Thus, high affinity agonist binding differs from low affinity 
agonist binding by an entropy gain. We then examined the 
question of whether this gain is caused by a Iiberation of cations 
during the binding reaction. The most likely candidate would 
be the sodium ion which is known to affect agonist binding to 
a2-receptors (12, 13). Assuming this Iiberation, the binding 
reaction for a hormone H and a receptor complex R would be: 
H + R ~ HR' + n·Na•. Then the logarithm of the observed 
association constant, K", would depend on the sodium concen-
tration: log K" =log K"' - n·log[Na•], with K"' representing 
the association constant without the sodium effect. 
Fig. 4 shows that, maintaining a constant ionic strength with 
the sodium substitute N-methyl-o-glucamine-which practi-
cally does not affect agonist binding to a2-receptors (12)-this 
dependence is indeed observed and is adequately fitted by the 
above equation. This gives an n value of 0. 7 for the high affinity 
and 0.2 for the low affinity agonist binding. The entropy 
increase ~o for the high affinity binding would be 0 for a 
sodium concentration of 300 mM. The contribution of this 
effect to the binding reaction can be calculated from the van •t 
Hoff equation using the K"' values. This Ieads to the estimate 
that a third of the high affinity-specific entropy gain is due to 
the Iiberation of sodium ions (difference of ~o values of high 
and low affinity binding of 18 cal/mol·deg for the K" values 
compared to 12 cal/mol·deg for the K"' values). 
The occurrence of a break point in the van't Hoffplots of all 
ligands at about 18° suggests that the binding to a2-receptors 
might be subject to membrane thermotropic phase transitions. 
The temperature at which these transitions occur can be low-
ered by addition of agents such as short chain fatty acids, with 
an optimum of seven to eight C-atoms (14, 15). These transi-
tions can be investigated by measuring the fluorescence of ANS 
(10, 16). The presence of low concentrations of ANS (10 ~tM) 
does not appear to alter phase transitions, whereas high con-
centrations (>1 mM) do (14). Fig. 5 shows the break points of 
the ANS fluorescence with platelet membranes in the absence 
and presence of 10 mM octanoic aicd. The data were best fitted 
by assuming two components, and break points were observed 
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Fig. 4. Effects of Na• on the association constants for (-)-epinephrine 
binding to arreceptors of human platelets. Competition experiments 
using 2 nM [3H]yohimbine were carried out at different concentrations of 
NaCI at 21 o. lonic strength was held constant by including N-methyl-o-
glucamine (adjusted to pH 7.4) so that the sum of the concentrations of 
these two cations was always 75 mM. Ko vaJues for [3H]yohimbine were 
determined in saturation experiments under these conditions and were 
used to calculate KH and KL vaJues as described for Fig. 3. KA values are 
1/KH and 1/KL. respectively. Data represent means from three experi-
ments and were fitted by linear regression. The slopes of the regression 
lines are 0.2 for the low (•) and 0.7 for the high (e) affinity binding. 
at about 17° in the absence and 12° in the presence of 10 mM 
octanoic acid. The same observations were made in the absence 
ofMg2•. 
If the break points in the van•t Hoffplots of Iigand binding 
were due to phase transitions reported by the ANS fluorescence 
measurement, then they should be shifted to lower tempera-
tures by addition of octanoic acid. Fig. 6 shows that the presence 
of 10 mM octanoic acid shifts the break point for yohimbine 
from about 18° to about 12°. The peak of the KA values is 
somewhat lower in the presence of octanoic seid. A similar 
effect of octanoic acid is seen for (-) -epinephrine binding to 
the low affinity state (Fig. 7). Again, a shift of the break point 
from about 18• to about 12° is observed. No such shift of the 
break point is observed for high affinity (-)-epinephrine bind-
ing. Here the break point occurs at about 18° both in the 
presence and in the absence of octanoic acid. The high affinity 
K" values are more reduced by octanoic acid than are the low 
affinity K" values. Thus, octanoic acid shifts the break points 
of antagonist and low affinity agonist binding in a manner 
similar to that of the break point of ANS fluorescence; high 
affinity agonist binding, however, is not susceptible to these 
changes. 
Discussion 
The investigation of the thermodynsmies of Iigand binding 
to receptors is thought to give insights into the fundamental 
differences between agonists and antagonists, which are re-
sponsible for their opposite effects on a given response (1). In 
the present study we used this approach to study the interaction 
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Fig. 5. ANS fluorescence measurements of human platelet membranes. 
Fluorescence of 1 0 #LM ANS in the presence of 400 #LQ of protein/ml of 
human platelet membranes was recorded in arbitrary units as described 
under Experimental Procedures (Methods) in the absence (0) and pres-
ence <•> of 1 0 mM octanoic acict Break points were determined as 
described under Experimental Procedures (Methods) and occurred at 
17° in the absence and at 12° in the presence of 1 0 mM octanoic acid 
· (arrows). Oata are the means of two separate experiments. 
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Fig. 6. Effects of octanoic acid on the van't Hoff plot of yohimbine 
binding. Saturation studies with [3H]yohimbine were canied out at differ-
ent temperatures and analyzed as described for Figs. 1 and 2. Open 
symbols indicate the absence and solid symbols the presence of 10 mM 
octanoic acid (adjusted to pH 7.4). Data represent means and SE of 
three experiments for each data point. 
of ligands with the a 2-receptor of human platelets. Our results 
support the hypothesis that this receptor exists in a high and 
a low affinity state for agonists being modulated by guanine 
nucleotides and divalent cations (8). Antagonists have the same 
affinity for the two states and, therefore, antagonist binding is 
not influenced by guanine nucleotides. U'Prichard et al. (17) 
have postulated a model with three affinity states for agonists; 
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Fig. 7. Effects of octanoic acid on the van't Hoffplots of (-)-epinephrine 
binding. Competition experiments using 2 nM [3H]yohimbine were carried 
out and analyzed as described for Fig. 3. Open symbols indicate the 
absence and solid symbols the presence of 1 0 mM octanoic acid (ad-
justed to pH 7.4). 0, e: high affinity state; 6., A: low affinity state. KA 
values are 1/KH and 1/K~.. respectively. Oata represent the rneans and 
SE of three to five experiments for each data point. 
however, in no case could we significantly improve the fitting 
of agonist binding data by assuming a third component. 
Changes in temperature do not affect the total number of 
binding sites. However, the effects on Iigand affinities for the 
a2-receptor appear to be more complex than in most other 
receptor systems examined so far. This is due to two facts: 1) 
the existence of break points in the van 't Hoff plots of both 
agonists and antagonists and 2) the heterogeneity of antagonist 
van't Hoff plots. Given the heterogeneous characteristics of 
antagonist binding, a comparison with agonist binding seems 
impossible, and agonist-specific changes cannot be deduced 
from such a comparison. A similar situation has been reported 
for the benzodiazepine receptor (18). Therefore, the results 
obtained for the ß-receptor (1) do not appear to be generally 
applicable. 
Differences between agonist and antagonist binding have 
been interpreted as being due to isomerization and/or coupling 
steps subsequent to agonist binding (1, 19). Prevention of these 
subsequent steps should allow an analysis of agonist-specific 
changes without the hazard of using another Iigand. This can 
be done in the case of adenylate cyclase-coupled receptors by 
an analysis of high and low affinity states of the receptor (6). 
Compared to the low affinity state, agonist binding to the high 
affinity state is characterized by an important entropy compo-
nent. Similar results have also been found for the At (R;) 
adenosine receptor (6). Such an entropy increase appears sur-
prising at first sight because high affinity agonist binding is 
thought to result in a more "ordered" ligand-receptor-Ni protein 
complex. Thus, the entropy gain must stem from additional 
processes such as effects of the solute or of ions. Since changes 
't 
of the solute result in loss of binding activity, we have studied 
only the role of ions. The results may be interpreted as follows. 
Sodium ions appear tobe associated with the receptor (or sites 
linked to the receptor). They dissociate in part upon agonist 
binding, and this effect is more pronounced for high affinity 
agonist binding (n = 0. 7) than for low affinity agonist binding 
(n = 0.2). The resultant entropy gain can be roughly estimated 
to contribute a third of the difference of binding energies 
between high and low affinity binding. The increased release 
of sodium for high affinity binding explains the observation of 
Michel et al. (13) that high affinity binding is influenced to a 
!arger degree than low affinity binding by raising the concen-
tration of sodium. The site of sodium action cannot be deter-
mined from the present study. The effect on low affinity agonist 
binding suggests that sodium Iiberation upon agonist binding 
occurs independently of Ni (20). The enhanced Iiberation upon 
high affinity binding may be due to either Iiberation from a site 
on Ni (21) or to enhancement ofliberation from a site regulated 
by coupling to N;. 
Breakpoints in the van't Hoffplots of ligand-receptor inter-
actions have not been observed for most receptors, although 
they are a common finding in enzymology. One exception is 
the benzodiazepine receptor, where a break point is also seen 
at about 18° for benzodiazepines (22) but not for the antagonist 
Ro 15-1788 (19). This break point is interpreted as being due 
to an agonist-specific isomerization step by Möhler and Rich-
ards (19), and as being due to a membrane phase transition by 
Speth et al. (23). Glossmann and Hornung (24) observed a 
discontinuity of the van't Hoffplot of clonidine binding to the 
a2-receptor of rat brain at 30°, which they interpreted as 
evidence for a thermal denaturation. There is indeed some loss 
of binding at high temperatures, but this cannot account quan-
titatively for the occurrence of a break point. 
Instead, our data support the hypothesis that the break 
points are due to membrane thermotropic phase transitions 
(23). Using the ANS fluorescence method, such a transition 
can be observed in the temperature range of the break point of 
Iigand binding. A shift of the transition temperature from 17° 
to 12° by addition of 10 mM octanoic acid is followed by a shift 
of the break point of antagonist binding. A similar shift is also 
seen for low affinity agonist binding, whereas the break point 
of high affinity agonist binding remains unchanged. Anionic 
compounds such as octanoic acid appear to selectively depress 
the phase transition temperature of the outer half of the plasma 
membrane (14, 25). These effects are reported by ANS, which 
interacts with the polar headgroups of the Iipids (26). Thus, 
antagonist and low affinity agonist binding are influenced by 
alterations occurring in the outer half of the plasma membrane. 
High affinity agonist binding is insensitive to such alterations, 
probably by coupling the receptor to N;. The resulting trans-
membrane complex appears to be little influenced by the outer 
half of the membrane. Several membrane proteins directed to 
the outside have been found tobe influenced by phase transi-
tions of the outer half of the plasma membrane (27, 28). 
Formation of the high affinity agonist state frees the a2-recep-
tor from such a regulation. This would allow selective regulation 
of agonist versus antagonist effects via the physical state of the 
plasma membrane. 
The temperature dependence of [3H]yohimbine binding is 
much less pronounced in the absence of Mg2+. However, the 
phase transitions reported by ANS were not altered by the 
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removal of Mg2+. This suggests that the coupling of the receptor 
to phase transitions of the plasma membrane may require Mg2+. 
Since Mg2+ is also needed to give stable binding conditions, we 
have not attempted a more detailed study of this phenomenon. 
To summarize, our data indicate that a comparison of the 
thermodynsmies of antagonist and agonist binding to a2-recep-
tors of human platelets does not allow the detection of agonist-
specific characteristics. Instead, we attempted to find agonist-
specific characteristics by comparing high and low affinity 
agonist binding. Two such characteristics emerged: an entropy 
gain which is responsible for the high affinity and which may 
in part be caused by enhanced Iiberation of sodium ions, and, 
second, an insensitivity to alterations of phase transitions in 
the outer half of the plasma membrane. The latter shows that 
agonist binding may be differentially regulated by the physical 
state of the plasma membrane. 
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